RT Generic
T1 Dr. Jekyll and Mr. Hyde: MAP17's up-regulation, a crosspoint in cancer and inflammatory diseases.
A1 Garcia-Heredia, Jose M
A1 Carnero, Amancio
K1 Cancer
K1 Inflammatory diseases
K1 MAP17
AB Inflammation is a common defensive response that is activated after different harmful stimuli. This chronic, or pathological, inflammation is also one of the causes of neoplastic transformation and cancer development. MAP17 is a small protein localized to membranes with a restricted pattern of expression in adult tissues . However, its expression is common in destabilized cells , as it is overexpressed both in inflammatory diseases and in cancer . MAP17 is overexpressed in most, if not all, carcinomas and in many tumors of mesenchymal origin, and correlates with higher grade and poorly differentiated tumors . This overexpression drives deep changes in cell homeostasis including increased oxidative stress , deregulation of signaling pathways and increased growth rates. Importantly, MAP17 is associated in tumors with inflammatory cells infiltration, not only in cancer but in various inflammatory diseases such as Barret’s esophagus , lupus, Crohn’s, psoriasis and COPD . Furthermore, MAP17 also modifies the expression of genes connected to inflammation , showing a clear induction of the inflammatory profile. Since MAP17 appears highly correlated with the infiltration of inflammatory cells in cancer , is MAP17 overexpression an important cellular event connecting tumorigenesis and inflammation ?
PB BioMed Central Ltd.
YR 2018
FD 2018-04-12
LK http://hdl.handle.net/10668/12341
UL http://hdl.handle.net/10668/12341
LA en
NO García-Heredia JM, Carnero A. Dr. Jekyll and Mr. Hyde: MAP17's up-regulation, a crosspoint in cancer and inflammatory diseases. Mol Cancer. 2018 Apr 12;17(1):80.
NO AC lab was supported by grants from the Spanish Ministry of Economy and Competitivity, Plan Estatal de I + D + I 2013-2016, ISCIII (Fis: PI15/00045) and CIBER de Cáncer (CB16/12/00275), co-funded by FEDER from Regional Development European Funds (European Union), Consejeria de Ciencia e Innovacion (CTS-1848) and Consejeria de Salud of the Junta de Andalucia (PI-0096-2014). We especially thank the AECC Foundation for supporting this work.
DS RISalud
RD May 9, 2025